Get the Stockscreener App
18.22
0.92%
-0.17
Janux Therapeutics Inc stock is traded at $18.22, with a volume of 385.46K.
It is down -0.92% in the last 24 hours and up +6.55% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
See More
Previous Close:
$18.39
Open:
$18.29
24h Volume:
385.46K
Relative Volume:
0.45
Market Cap:
$1.11B
Revenue:
$13.73M
Net Income/Loss:
$-114.48M
P/E Ratio:
-9.8925
EPS:
-1.8418
Net Cash Flow:
$-78.49M
1W Performance:
+10.16%
1M Performance:
+6.55%
6M Performance:
+22.04%
1Y Performance:
-31.27%
1-Day Range:
$17.96
$18.61
1-Week Range:
$16.31
$19.18
52-Week Range:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
18.22 | 1.11B | 13.73M | -114.48M | -78.49M | -1.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
508.18 | 128.80B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
212.45 | 84.82B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
765.73 | 78.84B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
818.73 | 51.49B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.48 | 41.47B | 742.00K | -1.37B | -1.07B | -7.0731 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-24-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-20-26 | Downgrade | Barclays | Overweight → Underweight |
| Apr-15-26 | Downgrade | UBS | Buy → Neutral |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-10-25 | Initiated | Stifel | Buy |
| Sep-10-25 | Initiated | Truist | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jul-11-25 | Initiated | Raymond James | Outperform |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains? - Zacks Investment Research
Janux Therapeutics (NasdaqGM:JANX) Stock Forecast & Analyst Predictions - Simply Wall Street
The first patient gets Janux's new immune treatment in a prostate cancer trial. - Stock Titan
Price-Driven Insight from (JANX) for Rule-Based Strategy - Stock Traders Daily
Janux’s JANX014 Prostate Cancer Trial Advances, Keeping Early-Stage Upside in Play - TipRanks
Understanding the Setup: (JANX) and Scalable Risk - Stock Traders Daily
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44% - qz.com
Wolfe Research Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $23 - Moomoo
Wolfe Research upgrades Janux stock rating on autoimmune data By Investing.com - Investing.com Canada
Wolfe Research upgrades Janux stock rating on autoimmune data By Investing.com - Investing.com India
Wolfe Research upgrades Janux stock rating on autoimmune data By Investing.com - Investing.com UK
Wolfe Research upgrades Janux stock rating on autoimmune data - investing.com
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know - TradingView
Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile? - Sahm
Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile? - simplywall.st
Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile? - simplywall.st
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $14 to $60 - Moomoo
Janux (JANX) Latest Quarter: EPS Lands Above Forecast; Market Reaction: Shares Finish 3.30% Higher on the DayEstimate Revision Count - vinanet.vn
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Sprott (SII) Trading Review: Retreats 3.40% to $117.79 for the Current Session; Price Context: Traders Can Monitor the $111.90-$123.68 Range under the Current SnapshotBollinger Walk - careplusvn.com
Dimensional Fund Advisors LP Has $1.34 Million Stake in Janux Therapeutics, Inc. $JANX - MarketBeat
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Ginkgo Bioworks Holdings (DNA) - The Globe and Mail
Point72 reports 3.3% beneficial stake in Janux Therapeutics (JANX) via managed fund - stocktitan.net
Janus Henderson Group (JANX) reports 172,229 Janux Therapeutics shares under management - stocktitan.net
William Blair Maintains Janux Therapeutics(JANX.US) With Buy Rating - moomoo.com
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Janux Therapeutics (JANX) Gains 0.91% as Shares Firmly Hold Above $15.84 SupportHigh Conviction Picks - Vinanet
Equities Analysts Set Expectations for JANX Q3 Earnings - MarketBeat
HC Wainwright Has Negative Outlook of JANX FY2030 Earnings - MarketBeat
Why (JANX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile - Yahoo Finance
Janus Living Prices Share Offering - marketscreener.com
Janus Living Prices Share Offering - Moomoo
RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating - Moomoo
Analysts Have Lowered Expectations For Janux Therapeutics, Inc. (NASDAQ:JANX) After Its Latest Results - simplywall.st
RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating - marketscreener.com
Janux Therapeutics (NASDAQ:JANX) Announces Earnings Results - MarketBeat
Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX) - theglobeandmail.com
Janux Therapeutics Inc (JANX) Stock News Today - TradingKey
Janux Therapeutics Inc (JANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $33.25, Implies 107% Upside - TradingView
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - BioSpace
JANX Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline Drives FocusRevenue Guidance Update - vinanet.vn
Janux Therapeutics earnings missed by $0.08, revenue fell short of estimates - Investing.com Canada
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Janux Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Janux Therapeutics 2Q 2026: Revenue $10.3M, EPS $(0.35) — 10-Q Summary - TradingView
JANX: Clinical pipeline advanced and net loss narrowed, supported by nearly $1B in liquidity - TradingView
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q2 Revenue $10.3M, vs. FactSet Est of $19.1M - marketscreener.com
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Janux Therapeutics Inc Stock (JANX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr |
Jun 02 '26 |
Sale |
14.03 |
4,059 |
56,944 |
75,941 |
| Janeen Noel Doyle | Officer |
Jun 02 '26 |
Proposed Sale |
14.03 |
4,059 |
56,944 |
0 |
| Dobek Maria | Vice President, Accounting |
May 11 '26 |
Sale |
14.17 |
2,038 |
28,878 |
32,270 |
| ANDY MEYER | Former Affiliate |
Apr 13 '26 |
Proposed Sale |
15.05 |
1,877 |
28,246 |
0 |
| ZACHARIAH A MCIVER | Former Officer |
Apr 02 '26 |
Proposed Sale |
14.65 |
74,802 |
1,095,761 |
0 |
| ANDY MEYER | Former Affiliate |
Jan 26 '26 |
Proposed Sale |
14.55 |
178,767 |
2,601,113 |
0 |
| ANDY MEYER | Former Affiliate |
Jan 23 '26 |
Proposed Sale |
14.72 |
118,122 |
1,738,390 |
0 |
| Campbell David Alan | President and CEO |
Jan 02 '26 |
Sale |
13.73 |
8,072 |
110,829 |
284,982 |
| Winter Charles M. | Chief Technical Officer |
Jan 02 '26 |
Sale |
13.73 |
2,401 |
32,966 |
77,721 |
| McIver Zachariah | Chief Medical Officer |
Jan 02 '26 |
Sale |
13.73 |
2,714 |
37,263 |
23,286 |
2.09%
8.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):